Nicolás Lamanna Rama

Dr. Nicolás Lamanna Rama

· Cardiovascular Risk Factors and Brain Health, Spanish National Centre for Cardiovascular Research, Madrid, Spain
orcid
Postodcoral Resercher

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
DRDiego Romero‐Miguel
Diego Romero‐Miguel
Nicolás Lamanna RamaNicolás Lamanna Rama
Nicolás Lamanna Rama
MCMarta Casquero‐Veiga
Marta Casquero‐Veiga
VGVanessa Gómez‐Rangel
Vanessa Gómez‐Rangel
DMDesco Menéndez Manuel
Desco Menéndez Manuel
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro

10 February 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Nicolás Lamanna RamaNicolás Lamanna Rama
Nicolás Lamanna Rama
DRDiego Romero-Miguel
Diego Romero-Miguel
DMDesco Menéndez Manuel
Desco Menéndez Manuel
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro
Curcumin is a polyphenol extracted from the rhizome of the turmeric plant. Beyond its common use as a culinary spice in Eastern Asia, curcumin has been proposed as a therapeutic compound due to its antioxidant, anti-inflammatory and neuroprotective properties. Thus, its efficacy has been evaluated in various inflammatory-based psychiatric disorders, such as schizophrenia, depression, or autism. Our aim is to review those preclinical and clinical studies carried out in psychiatric disorders whose therapeutic approach has involved the use of curcumin and, therefore, to discern the possible positive effect of curcumin in these disorders. Preclinical studies and completed clinical trials of curcumin for psychiatric disorders published from January 2005 to October 2021 were identified through searching relevant databases until 31st October 2021. Sixty-five preclinical studies and 15 clinical trials and open-label studies were selected. Results showed a bias toward studies in depression and, to a lesser extent, schizophrenia. In all disorders, the results were positive in reducing psychiatric deficits. Despite the considerable number of beneficial outcomes reported, the small number of trials and the heterogeneity of protocols make it difficult to draw solid conclusions about the real potency of curcumin in psychiatric disorders.

1 May 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MCMarta Casquero-Veiga
Marta Casquero-Veiga
DRDiego Romero-Miguel
Diego Romero-Miguel
KMKarina S. MacDowell
Karina S. MacDowell
STSonia Torres-Sanchez
Sonia Torres-Sanchez
JGJose Antonio Garcia-Partida
Jose Antonio Garcia-Partida
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro

24 June 2021 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
DRDiego Romero-Miguel
Diego Romero-Miguel
MCMarta Casquero-Veiga
Marta Casquero-Veiga
KMKarina S MacDowell
Karina S MacDowell
STSonia Torres-Sanchez
Sonia Torres-Sanchez
JGJosé Antonio Garcia-Partida
José Antonio Garcia-Partida
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro
Background: Minocycline (MIN) is a tetracycline with antioxidant, anti-inflammatory, and neuroprotective properties. Given the likely involvement of inflammation and oxidative stress (IOS) in schizophrenia, MIN has been proposed as a potential adjuvant treatment in this pathology. We tested an early therapeutic window, during adolescence, as prevention of the schizophrenia-related deficits in the maternal immune stimulation (MIS) animal model. Methods: On gestational day 15, Poly I:C or vehicle was injected in pregnant Wistar rats. A total 93 male offspring received MIN (30 mg/kg) or saline from postnatal day (PND) 35–49. At PND70, rats were submitted to the prepulse inhibition test. FDG-PET and T2-weighted MRI brain studies were performed at adulthood. IOS markers were evaluated in frozen brain tissue. Results: MIN treatment did not prevent prepulse inhibition test behavioral deficits in MIS offspring. However, MIN prevented morphometric abnormalities in the third ventricle but not in the hippocampus. Additionally, MIN reduced brain metabolism in cerebellum and increased it in nucleus accumbens. Finally, MIN reduced the expression of iNOS (prefrontal cortex, caudate-putamen) and increased the levels of KEAP1 (prefrontal cortex), HO1 and NQO1 (amygdala, hippocampus), and HO1 (caudate-putamen). Conclusions: MIN treatment during adolescence partially counteracts volumetric abnormalities and IOS deficits in the MIS model, likely via iNOS and Nrf2–ARE pathways, also increasing the expression of cytoprotective enzymes. However, MIN treatment during this peripubertal stage does not prevent sensorimotor gating deficits. Therefore, even though it does not prevent all the MIS-derived abnormalities evaluated, our results suggest the potential utility of early treatment with MIN in other schizophrenia domains.

20 April 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
DRDiego Romero-Miguel
Diego Romero-Miguel
MCMarta Casquero-Veiga
Marta Casquero-Veiga
JFJavier Fernández
Javier Fernández
Nicolás Lamanna RamaNicolás Lamanna Rama
Nicolás Lamanna Rama
VGVanessa Gómez-Rangel
Vanessa Gómez-Rangel
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro
The microbiota-gut-brain axis is a complex interconnected system altered in schizophrenia. The antioxidant N-acetylcysteine (NAC) has been proposed as an adjunctive therapy to antipsychotics in clinical trials, but its role in the microbiota-gut-brain axis has not been sufficiently explored. We aimed to describe the effect of NAC administration during pregnancy on the gut-brain axis in the offspring from the maternal immune stimulation (MIS) animal model of schizophrenia. Pregnant Wistar rats were treated with PolyI:C/Saline. Six groups of animals were studied according to the study factors: phenotype (Saline, MIS) and treatment (no NAC, NAC 7 days, NAC 21 days). Offspring were subjected to the novel object recognition test and were scanned using MRI. Caecum contents were used for metagenomics 16S rRNA sequencing. NAC treatment prevented hippocampal volume reduction and long-term memory deficits in MIS-offspring. In addition, MIS-animals showed lower bacterial richness, which was prevented by NAC. Moreover, NAC7/NAC21 treatments resulted in a reduction of proinflammatory taxons in MIS-animals and an increase in taxa known to produce anti-inflammatory metabolites. Early approaches, like this one, with anti-inflammatory/anti-oxidative compounds, especially in neurodevelopmental disorders with an inflammatory/oxidative basis, may be useful in modulating bacterial microbiota, hippocampal size, as well as hippocampal-based memory impairments.

27 November 2023 in Psychiatry Research
Verified
Journal Article
Closed access
Nicolás Lamanna RamaNicolás Lamanna Rama
Nicolás Lamanna Rama
DRDiego Romero-Miguel
Diego Romero-Miguel
MCMarta Casquero-Veiga
Marta Casquero-Veiga
KMKarina MacDowell
Karina MacDowell
CSCristina Santa-Marta
Cristina Santa-Marta
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro